tyrosyl-arginyl-phenylalanyl-lysinamide has been researched along with naltrexone in 3 studies
| Studies (tyrosyl-arginyl-phenylalanyl-lysinamide) | Trials (tyrosyl-arginyl-phenylalanyl-lysinamide) | Recent Studies (post-2010) (tyrosyl-arginyl-phenylalanyl-lysinamide) | Studies (naltrexone) | Trials (naltrexone) | Recent Studies (post-2010) (naltrexone) |
|---|---|---|---|---|---|
| 74 | 0 | 17 | 8,745 | 1,228 | 2,642 |
| Protein | Taxonomy | tyrosyl-arginyl-phenylalanyl-lysinamide (IC50) | naltrexone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0051 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0063 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.006 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.006 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.0319 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0093 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0377 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0076 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lishmanov, IuB; Maslov, LN; Naryzhnaia, NV | 1 |
| Maslov, LN; Naryzhnaya, NV; Tam, SW | 1 |
| Neilan, CL; Nguyen, TM; Pasternak, GW; Schiller, PW | 1 |
3 other study(ies) available for tyrosyl-arginyl-phenylalanyl-lysinamide and naltrexone
| Article | Year |
|---|---|
[Cardioprotective effects of stimulation of peripheral mu-opiate receptors, and the role of opiatergic mechanisms in the pathogenesis of stress-induced heart damage].
Topics: Animals; Cardiomyopathies; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Immobilization; Male; Naltrexone; Narcotic Antagonists; Oligopeptides; Rats; Rats, Wistar; Receptors, Opioid, mu; Stress, Physiological | 1997 |
Ligands for opioid and sigma-receptors improve cardiac electrical stability in rat models of post-infarction cardiosclerosis and stress.
Topics: Animals; Anti-Arrhythmia Agents; beta-Endorphin; Disease Models, Animal; Dynorphins; Enkephalin, Leucine-2-Alanine; Heart; Immobilization; Ligands; Morphine; Myocardial Infarction; Myocardium; Naloxone; Naltrexone; Narcotic Antagonists; Oligopeptides; Piperidines; Pyrrolidines; Rats; Receptors, Opioid; Receptors, Opioid, delta; Stress, Physiological; Ventricular Fibrillation | 1999 |
Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide.
Topics: Analgesics; Animals; Drug Tolerance; Humans; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Oligodeoxyribonucleotides, Antisense; Oligopeptides; Opioid Peptides; Pain Measurement; Receptors, Opioid, mu; Time Factors | 2001 |